State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer - European Medical Journal

Continue

State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer

Oncology
Download PDF
Authors:
*Elena Castro,1,2 Nuria Romero,1,2 David Olmos1,2

1. Prostate Cancer and Genitourinary Tumours Unit, Clinical Research Programme, Spanish National Cancer Research Centre, Madrid, Spain
2. Prostate cancer unit, Clara Campal Comprehensive Cancer Center, HM Universitario Sanchinarro, Madrid, Spain
*Correspondence to [email protected]

Disclosure:

No potential conflict of interest.

Received:
22.05.14
Accepted:
09.09.14
Citation:
EMJ Oncol. ;2[1]:100-105. DOI/10.33590/emjoncol/10310799. https://doi.org/10.33590/emjoncol/10310799.
Keywords:
Prostate cancer, renal cancer, bladder cancer, testicular cancer, treatment options.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Abstract

Prostate cancer (PrCa) is the most common cancer type in men in developed countries. In the last few years, a dramatic change has occurred in the understanding of castration-resistant PrCa which has led to the development of new drugs that have an impact on patient survival. This review summarises the recent advances in the management of the disease.

Please view the full content in the pdf above.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.